Substance / Medication

Darolutamide

Overview

Active Ingredient
darolutamide
RxNorm CUI
2180325
Labeler: Bayer HealthCare Pharmaceuticals Inc.Updated: 2025-10-29T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

2 trials linked to this intervention

2
Total Trials
2
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Safety profile of darolutamide versus placebo: a systematic review and meta-analysis.
Turco Fabio, Gillessen Silke, Treglia Giorgio et al. · Prostate Cancer Prostatic Dis · 2024
PMID: 38097723Meta-Analysis
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
Mori Keiichiro, Mostafaei Hadi, Pradere Benjamin et al. · Int J Clin Oncol · 2020
PMID: 32924096Meta-AnalysisFull text (PMC)
Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS.
Morgans Alicia K, Grossman Jamie Partridge, Paracha Noman et al. · J Manag Care Spec Pharm · 2024
PMID: 38807035RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Darolutamide (substance)
SNOMED CT
789148001
UMLS CUI
C4547776
RxNorm CUI
2180325
Labeler
Bayer HealthCare Pharmaceuticals Inc.

Clinical Data

This intervention maps to 5 entities in the Healos knowledge graph.

1
Conditions
1
Biomarkers
2
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.